Literature DB >> 25691771

CCR 20th Anniversary commentary: stayin' alive-antiapoptotic proteins and breast cancer.

Douglas Yee1.   

Abstract

The control of cell death involves a complex interaction of multiple proteins. In a study published in the January 1, 2000, issue of Clinical Cancer Research, Tanaka and colleagues demonstrated that one of the proapoptotic proteins, survivin, was frequently expressed in breast cancer. In the subsequent years, effectors of apoptosis have translated into important prognostic indicators and potential therapeutic targets. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25691771      PMCID： PMC4333724          DOI： 10.1158/1078-0432.CCR-14-2548

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Expression of survivin and its relationship to loss of apoptosis in breast carcinomas.

Authors:  K Tanaka; S Iwamoto; G Gon; T Nohara; M Iwamoto; N Tanigawa
Journal:  Clin Cancer Res       Date:  2000-01       Impact factor: 12.531

2.  A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer.

Authors:  Paweł Wiechno; Bradley G Somer; Begoña Mellado; Piotr L Chłosta; José Manuel Cervera Grau; Daniel Castellano; Christoph Reuter; Michael Stöckle; Jörn Kamradt; Joanna Pikiel; Ignacio Durán; Steffen Wedel; Sophie Callies; Valérie André; Karla Hurt; Jacqueline Brown; Michael Lahn; Bernhard Heinrich
Journal:  Eur Urol       Date:  2013-11-06       Impact factor: 20.096

3.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

Review 4.  Treatment of HER2-positive breast cancer: current status and future perspectives.

Authors:  Carlos L Arteaga; Mark X Sliwkowski; C Kent Osborne; Edith A Perez; Fabio Puglisi; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2011-11-29       Impact factor: 66.675

5.  Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.

Authors:  Ronald Natale; Fiona Blackhall; Dariusz Kowalski; Rodryg Ramlau; Gerold Bepler; Francesco Grossi; Christian Lerchenmüller; Mary Pinder-Schenck; Jörg Mezger; Sarah Danson; Shirish M Gadgeel; Yvonne Summers; Sophie Callies; Valérie André; Mayukh Das; Michael Lahn; Denis Talbot
Journal:  J Thorac Oncol       Date:  2014-11       Impact factor: 15.609

Review 6.  Targeting survivin in cancer.

Authors:  Dario C Altieri
Journal:  Cancer Lett       Date:  2012-03-09       Impact factor: 8.679

Review 7.  S-phase fraction and breast cancer--a decade of experience.

Authors:  C R Wenger; G M Clark
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

Review 8.  Treat cancers by targeting survivin: just a dream or future reality?

Authors:  Mohane Selvaraj Coumar; Fang-Ying Tsai; Jagat Rakesh Kanwar; Sailu Sarvagalla; Chun Hei Antonio Cheung
Journal:  Cancer Treat Rev       Date:  2013-02-28       Impact factor: 12.111

9.  A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

Authors:  R J Kelly; A Thomas; A Rajan; G Chun; A Lopez-Chavez; E Szabo; S Spencer; C A Carter; U Guha; S Khozin; S Poondru; C Van Sant; A Keating; S M Steinberg; W Figg; G Giaccone
Journal:  Ann Oncol       Date:  2013-07-14       Impact factor: 51.769

Review 10.  Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.

Authors:  J F Kerr; A H Wyllie; A R Currie
Journal:  Br J Cancer       Date:  1972-08       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.